337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials

Hassanieh, S., Domingo, E., Blake, A. et al. (16 more authors) (2022) 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. In: Annals of Oncology. ESMO Congress 2022, 09-13 Sep 2022, Paris, France. Elsevier , S691.

Metadata

Authors/Creators:
Dates:
  • Published (online): 13 September 2022
  • Published: 13 September 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Pathology and Data Analytics
Funding Information:
FunderGrant number
Cancer Research UK Supplier No: 138573RCS REF 08-0843 SUBCONTR
Cancer Research UK Supplier No: 138573C6003/A7367
Cancer Research UK Supplier No: 138573C7852/A19772
Cancer Research UK Supplier No: 138573C6003/A3830
MRC (Medical Research Council)NOT GIVEN
Leeds Hospitals Charity1T01-A321
Leeds Teaching Hospitals Charitable Foundation4616
Depositing User: Symplectic Publications
Date Deposited: 17 Jul 2023 08:14
Last Modified: 17 Jul 2023 08:14
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.annonc.2022.07.475
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics